Group 1: Company Strategy and Development - The company will continue to focus on high-quality development, emphasizing talent as the foundation and innovation-driven strategies [2] - Future strategic areas include digestive, ENT, and mental health fields, with plans to expand into cancer, immunity, respiratory, and metabolic diseases [2][3] - The company aims to enhance its R&D capabilities to be among the top in China within the 14th Five-Year Plan, targeting over 2 innovative drug clinical approvals and 3 clinical candidate compounds [3] Group 2: Financial Performance - In 2022, the company achieved operating revenue of CNY 785 million, a decrease of 7.2% year-on-year, but showed a recovery with Q4 revenue of CNY 223.49 million, an increase of 11.3% [4][5] - The net profit attributable to shareholders was CNY 98.4 million, up 7.21% year-on-year, driven by increased sales of core products [5] - The company’s asset-liability ratio improved from 27.33% at the end of Q3 2022 to 13.73% by the end of 2022, enhancing its risk resistance [5][7] Group 3: R&D Investment - R&D investment in 2022 was CNY 93.27 million, accounting for 11.88% of revenue, with a compound annual growth rate of 33.77% over three years [7] - The company has established a "three-three-three" pipeline structure, aiming for at least three projects to be initiated, filed, and launched each year [3][8] - The company plans to launch at least three new drug varieties annually over the next five years [8] Group 4: Market and Product Development - The company is actively preparing for the integration of proprietary traditional Chinese medicine (TCM) products into national procurement systems [6][8] - The company has built a production base for special medical foods in the Sichuan-Chongqing region, with plans to obtain production licenses within 2-3 years [7] - The company is leveraging digital marketing and new media to promote its health products and expand market reach [8]

重庆华森制药股份有限公司 关于盐酸丁螺环酮片获得美国 FDA 新增生产场地批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到了美国食品药品监督 管理局（以下简称"美国 FDA"）签发的关于盐酸丁螺环酮片（ANDA#208972）新增药品 生产场地的 PAS（Prior Approval Supplement）批准的通知，现将相关信息公告如下： 一、 药品相关情况 证券代码：002907 证券简称：华森制药 公告编号：2023-042 二、药品其他情况 盐酸丁螺环酮片主要适用于焦虑症的管理或焦虑症状的短期缓解，属于国家基药、 国家医保药物，为芳香族哌嗪类抗焦虑药，是一种 5-HT1A 受体激动剂，治疗广泛性焦 虑症和其他焦虑性障碍。其机制为选择性作用于 5-HT1A 受体，通过下调 5-HT 功能而起 到抗焦虑作用。因其特异性高，且无明显镇静、催眠、肌肉松弛以及引起依赖或戒断反 应等不良反应，目前已广泛适用于精神科各种焦虑症的治疗，亦可用于治疗躯体疾病伴 发的焦虑状态，被中外焦虑障碍治疗指南均推荐为 ...

证券代码：002907 证券简称：华森制药 公告编号：2023-041 重庆华森制药股份有限公司 关于获得平消片药品补充申请批准通知书 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的关于平消片的《药品补充申请批准 通知书》，将变更平消片药品说明书中安全性等内容以及变更药品规格，规范规 格项的表述。现就相关情况公告如下： 一、药品基本信息 | 药 | 品 | | 名 | 称：平消片 | | --- | --- | --- | --- | --- | | 剂 | | | | 型：片剂 | | 注 | 册 | | 分 | 类：中药 | | 规 | | | | 格：每片重 0.24g（相当于饮片 0.405g） | | 受 | | 理 | | 号：CYZB2301197 | | 通 | 知 | 书 | 编 | 号：2023B04894 | | 原 | | | 药 品 批 准 文 号：国药准字 | Z21021130 | | 申 | 请 | | 内 | ...

证券代码：002907 证券简称：华森制药 公告编号：2023-040 重庆华森制药股份有限公司 关于获得胆舒软胶囊药品补充申请批准通知书 | 药 | 品 | | 名 | 称：胆舒软胶囊 | | --- | --- | --- | --- | --- | | 剂 | | | | 型：胶囊剂 | | 注 | 册 | | 分 | 类：中药 | | 规 | | | | 格：每粒装 0.27g | | 受 | | 理 | | 号：CYZB2301196 | | 通 | 知 | 书 | 编 | 号：2023B04382 | | 原 | | | | 药 品 批 准 文 号：国药准字 Z20080091 | | 申 | 请 | | 内 | 容：变更药品说明书中安全性等内容 | 审 批 结 论：根据《中华人民共和国药品管理法》及有关规定，经 审查，本品符合药品注册的有关要求，批准本品变更 药品说明书中安全性等内容的补充申请。具体修订如 下：【不良反应】监测数据显示，本品可见恶心、呕 吐、胃痛、皮疹、瘙痒等不良反应，有用药后出现肝 功能异常的个例报告。【禁忌】对本品及所含成份过 敏者禁用。【注意事项】1.忌烟、酒及辛辣、生冷、 ...

证券代码:002907 证券简称:华森制药 | --- | --- | --- | --- | |--------------------|-------------------------------|-------------|----------------------| | | | | 编号:2023-007 | | | □特定对象调研 | □分析师会议 | | | | □媒体采访 | ■业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | □其他(请文字说明其他活动内容) | | | | 参与单位名称及 | 通过"路演中"网络平台参与公司 | 2023 | 年半年度网上业绩说明 | 人员姓名 会的投资者 时间 2023 年 9 月 1 日 地点 公司 2 楼会议室 游洪涛(董事长) 秦少容(独立董事) 上市公司接待人姓名 游雪丹(副总经理、董事会秘书) 彭晓燕(财务总监) 周智如(证券事务代表) 一、公司在遵守信息披露制度的前提下,介绍公司经营业 绩、产品布局、市场开发和生产管理等情况,沟通内容与公司 公告内容一致。 二、采取问 ...

证券代码：002907 证券简称：华森制药 公告编号：2023-039 重庆华森制药股份有限公司 二、参加人员 届时，公司董事长、独立董事、总经理、财务总监、董事会秘书等主要领导将 出席本次业绩网上说明会（如有特殊情况，参与人员会有调整）。 三、投资者参加方式 投资者可登陆"路演中"（http://www.roadshowchina.cn/）预约参与本次半年度 业绩网上说明会。 四、公开征集问题 为充分尊重投资者，广泛听取投资者的意见和建议，现就公司2023年半年度业 绩说明会提前向投资者公开征集问题，提问通道自发出公告之日起开放。投资者可 于2023年8月31日（星期四）17:00前将有关问题通过电子邮件的形式发送至公司投资 者关系邮箱（ir@pharscin.com）。公司将在2023年半年度业绩说明会上，对投资者 普遍关注的问题进行回答。欢迎广大投资者积极参与。 关于举行2023年半年度业绩网上说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称 "公司"）《2023年半年度报告》全文 及其摘要已于2023年8 ...

证券代码：002907 证券简称：华森制药 公告编号：2023-037 重庆华森制药股份有限公司 关于公司药品生产许可证变更的公告 本 公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 生产地址和生产范围：重庆市荣昌区工业园区：软胶囊剂，小容量注射剂，散 剂，冻干粉针剂，原料药，颗粒剂，粉针剂，硬胶囊 剂，片剂，中药前处理及提取，吸入溶液剂，滴剂*** 重庆市荣昌区昌州街道板桥路 143 号：粉针剂，冻干粉 针剂，片剂，硬胶囊剂，软胶囊剂，颗粒剂，散剂，中 药前处理及提取，中药饮片，滴剂（胶囊剂）*** 三、产品情况说明 近年来，儿科中成药市场再创新高，根据米内网数据显示，2022年中国零售药 店（城市实体药店+网上药店）终端儿科中成药销售额超过 72 亿元，同比增长 19.47%。其中，儿科中成药网上药店销售占比为10.59%，儿科止咳祛痰用药、儿科 感冒用药是儿科中成药实体药店市场的销售主力，实体药店仍然是儿科中成药零售 市场主渠道。小儿咽扁颗粒是中国城市实体药店终端儿科中成药品牌 TOP20 产品之 一，具有清热利咽，解毒止痛的作用，适用于小儿肺卫热盛所致的 ...

证券代码：002907 证券简称：华森制药 公告编号：2023-038 重庆华森制药股份有限公司 关于获得小儿咽扁颗粒药品补充申请批准通知书暨 成为药品上市许可持有人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的关于小儿咽扁颗粒（每袋装 4g、 每袋装 8g）的《药品补充申请批准通知书》，并已完成药品生产许可证变更（详 见公司公告，公告编号 2023-037），标志着该产品已完成药品上市许可持有人 变更工作，公司已成为其药品上市许可持有人，公司将尽快开展市场营销工作。 现就相关情况公告如下： 二、药品基本信息 1.小儿咽扁颗粒（4g） 上 市 许 可 持 有 人：名称：重庆华森制药股份有限公司 地址：重庆市荣昌区工业园区 生产企业：名称：山西迈迪制药有限公司 药品名称：小儿咽扁颗粒 剂 型：颗粒剂 注册分类：中药 规 格：每袋装 4g 受理号：CYZB2301406 通知书编号：2023B04087 原 药 品 批 准 文 号：国药准字 Z1 ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2023, representing a year-on-year increase of 15% compared to 2022[17]. - The net profit attributable to shareholders reached 80 million CNY, up 20% from the same period last year[17]. - The company's operating revenue for the first half of 2023 was ¥360,455,416.63, a decrease of 1.95% compared to ¥367,627,972.49 in the same period last year[23]. - The net profit attributable to shareholders was ¥41,362,119.74, down 20.42% from ¥51,973,460.14 year-on-year[23]. - The basic earnings per share decreased by 23.61% to ¥0.0990 from ¥0.1296 in the previous year[23]. - The company achieved an operating profit of 47.14 million yuan, a decline of 23.37% compared to the same period last year; total profit was 47.20 million yuan, down 22.75% year-on-year[39]. - The company reported a total comprehensive income of CNY 42,124,450.36 for the first half of 2023, compared to CNY 52,174,103.04 in the same period of 2022[177]. - The company reported a net profit of -8,584,102.91 CNY from its subsidiary Beijing Huason Yingnuo Biotechnology Co., Ltd., with no operating revenue during the reporting period[82]. Research and Development - The company has invested 30 million CNY in R&D for new technologies, focusing on biopharmaceuticals and digital health solutions[17]. - R&D expenses increased by 36.21% year-on-year, accounting for 8.02% of revenue, which is an increase of 2.25 percentage points compared to the previous year[39]. - The company is focusing on R&D innovation, with four self-developed oncology class 1 innovative drugs currently in the pipeline[35]. - The company has applied for 9 innovative drug compound patents during the reporting period, including 2 PCT patents; as of the end of the reporting period, a total of 11 innovative drug compound patents have been applied for, with 4 PCT patents and 1 granted[42]. - The company is focusing on high-end complex formulations and innovative drugs, aiming for breakthroughs in higher technical barriers[42]. Market Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[17]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[17]. - The company aims to launch at least three new products annually, with ongoing market promotion for new varieties such as the compound omeprazole sodium bicarbonate capsules and the national essential medicine Pingxiao tablets[50]. - The company is actively pursuing international market opportunities, with plans to enter at least two new overseas markets by the end of 2024[141]. - The company is expanding its market presence, targeting an additional 10 provinces in China by the end of 2023, which is expected to contribute an estimated 200 million yuan in additional revenue[134]. Product Development - New product launches include two innovative drugs expected to enter the market by Q4 2023, projected to generate an additional 50 million CNY in revenue[17]. - The company is developing three special medical food projects, which are currently in stability testing and documentation preparation stages[31]. - The company has established the first special medical food production base in the Sichuan-Chongqing region, completed in June 2022[31]. - The company has a total of 75 approved drug products, with 20 included in the National Essential Medicines List and 54 in the National Medical Insurance Directory[31]. - The company has successfully launched new products, including a tablet formulation that has received regulatory approval, contributing to its market expansion efforts[141]. Financial Guidance and Strategy - Future guidance estimates a revenue growth of 12% for the second half of 2023, with a target of 560 million CNY[17]. - The company has set a performance guidance for the full year 2023, projecting a revenue growth of 20% and a net profit increase of 15%[137]. - The company plans to continue leveraging new media marketing platforms to explore growth opportunities in the health consumption market[52]. - The company plans to invest 150 million yuan in technology upgrades to streamline operations and improve efficiency in production processes[134]. - The company is committed to improving operational efficiency and optimizing its product portfolio to meet market demands[199]. Risk Management - Risk factors include regulatory changes and market competition, which the company is actively monitoring and addressing[4]. - The company has not reported any significant changes in risks and countermeasures compared to the previous year[83]. Environmental Compliance - The company has maintained compliance with environmental regulations, with all wastewater, waste gas, noise, and solid waste emissions meeting the required standards[92]. - The company has received ISO14001 environmental management system certification, valid until December 9, 2023[102]. - The company has implemented sound insulation and vibration reduction measures to manage noise pollution[97]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[88]. - The total number of common shareholders at the end of the reporting period is 30,176[154]. - The largest shareholder, Chengdu Local Construction Machinery Co., Ltd., holds 45.04% of the shares, totaling 188,100,000 shares[155].

根据中国证监会《上市公司监管指引第 8 号——上市公司资金往来、对外担保 的监管要求》的规定和要求，对公司 2023 年上半年度关联方占用公司资金情况和对 外担保情况进行了认真的核查，现发表如下独立意见： 重庆华森制药股份有限公司 关于第三届董事会第八次会议相关事项的独立意见 根据《中华人民共和国公司法》、《上市公司独立董事规则》、《上市公司治理 准则》、《深圳证券交易所股票上市规则》、以及《公司章程》等有关规定，我们作 为重庆华森制药股份有限公司（以下简称"公司"）的独立董事，经认真审查相关料 后，对公司第三届董事会第八次会议审议的相关议案及事项发表如下独立意见： 一、关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和 独立意见： （一）2023 年上半年度，公司不存在控股股东及其他关联方违规占用公司资金的 情况，也不存在以前期间发生延续至报告期的控股股东及其他关联方违规占用公司资 金的情况。 （二）2023 年上半年度，公司无任何形式的违规对外担保，也无以前期间发生延 续到报告期的违规对外担保事项。 （以下无正文） （此页无正文，为重庆华森制药股份有限公司第三届董事会第八次会议相关事项 的 ...